RxDoctor Payments Data

Jiade Yu, MD

Pediatric Dermatology · Boston, MANPI 1538421961

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $56,170 of the $69,748 with a category attached, or 80.5%. 10 manufacturers reported payments, led by LEO Pharma Inc. at 31.6% of the total.

$69,748in general payments, 2019–2025

Across 57 payments — averaging $1223.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$22K
  • Sanofi$20K
  • Arcutis Biotherapeutics, Inc.$9K
  • Incyte Corporation$7K
  • Dermavant Sciences, Inc.$4K
  • Allerderm Laboratories$3K
  • plus $4K from 4 others
$82,680in research payments, 2019–2025

Across 25 payments — averaging $3307.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$34K
  • AbbVie$28K
  • Incyte Corporation$19K
  • Regeneron$1K

What the payments were for

  • Consulting fees$56,17081%
  • Speaking & faculty fees$7,38411%
  • Travel & lodging$2,2543%
  • Food & beverage$1,4162%
  • Education$2,5254%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric dermatology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$65,678
Medicare patients
186
Services billed
4,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab56$247,467
Dupixent PenDupilumab59$200,262
Humira PenAdalimumab12$82,594
Tacrolimus19$3,916
Clobetasol Propionate34$2,585
Fluocinonide19$968
Triamcinolone Acetonide43$702
Ketoconazole32$436
MethotrexateMethotrexate Sodium20$300
Prednisone14$43

Paid to pharmacies, not to this prescriber.

Other pediatric dermatology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →